fda warning bpc 157 tb 500 bpc-157 peptide products unapproved BPC-157 / TB-500 (Tβ4) Blend is bpc 157 approved in

In a formal review, the agency concluded that BPC-157: Lacks sufficient safety data and has not been shown to be safe or effective in humans FDA Compounding Memorandum, 2023 The FDA also lists BPC-157 as ineligible for 503B compounding , which prohibits it from being added to compounded medications by outsourcing facilities

The omission of batch-testing by numerous online vendors indicates that the issue of risk often relates to product quality rather than solely the inherent properties of the peptide

After 3 months, take a 2-month break before repeating

Radiation exposure (the extra risk of developing cancer over a lifetime: on average less than 1 in 3,000)

What experts say about peptides and long-term safety We dont know enough about injectable peptides to say what kinds of effects they may have on long-term health or safety